Search Results

Featured Stories

Toggle

Showing 25 of 1689 results

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

Teva to Present at the Barclays Global Healthcare Conference

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

Teva Finalizes Nationwide Opioid Settlement Terms

Teva Announces Appointment of Richard Francis as President and CEO

Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform

Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting

Teva Reports Third Quarter 2022 Financial Results

Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease